ReviewSeminars in respiratory and critical care medicine2015
Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis.
Review in Seminars in respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 109 citations in OpenAlex.
- Effects of erythromycin dosage on clinical outcomes in stable non-cystic fibrosis bronchiectasis: A randomized controlled trial.Medicine · 2025Trial
- Tobramycin enhancesProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Activation of the antibiotic resistance factor WhiB7 can stimulate aggregate biofilm formation in stationary phaseJournal of bacteriology · 2026Article
- Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacteriumabscessus.The Journal of biological chemistry · 2026Article
- Zebrafish larvae swim bladder serves as a model to studyMycobacteria (London, England) · 2026Article
- Finding the optimal regimen forBMJ open · 2025Article
- Cell envelope polysaccharide modifications alter the surface properties and interactions ofmBio · 2025Article
- Serratia sp. traits distinguish the lung microbiome of patients with tuberculosis and non-tuberculous mycobacterial lung diseases.PloS one · 2025Article
- The DosR regulon ofFrontiers in cellular and infection microbiology · 2025Article
- Diagnostic Value of Targeted Next-generation Sequencing in Pulmonary Mycobacterial Infections.Current medical science · 2024Article
- Rapid lateral flow test for Mycobacterium tuberculosis complex and non-tuberculous mycobacteria differentiation.Applied microbiology and biotechnology · 2024Article
- An optimized cyclophosphamide-treated mouse model ofAntimicrobial agents and chemotherapy · 2024Article
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
- Broad-Spectrum In Vitro Activity ofAntibiotics (Basel, Switzerland) · 2024Article
- Lipoarabinomannan modification as a source of phenotypic heterogeneity in host-adaptedProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Nontuberculous Mycobacteria, Mucociliary Clearance, and Bronchiectasis.Microorganisms · 2024Review
- Nitric oxide-releasing prodrug for the treatment of complexAntimicrobial agents and chemotherapy · 2024Article
- A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2023Article
- Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype.Biofilm · 2023Article
- Dectin-1-Independent Macrophage Phagocytosis ofInternational journal of molecular sciences · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Increasing numbers of cystic fibrosis (CF) and non-CF bronchiectasis patients are affected by pulmonary nontuberculous mycobacteria (NTM) infection worldwide. Two species of NTM account for up to 95% of the pulmonary NTM infections: Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABSC). Diagnosis of pulmonary NTM infection is based on criteria specified in the 2007 American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guidelines. While many initial positive cultures do not progress to active NTM disease, even a single positive NTM sputum culture obtained from higher risk groups such as classic CF or older women with bronchiectasis and very low body mass index should be closely monitored for progressive disease. Macrolides remain the most effective agents available against MAC and MABSC. Infection with MABSC may be associated with worse clinical outcomes, as more than half of MABSC isolates have inducible macrolide resistance conferred by an active erm(41) gene. Of growing concern in CF is that MABSC is becoming more common than MAC, seems to target younger patients with classic CF, and is more difficult to manage, often requiring prolonged courses of intravenous antibiotics. Recurrence rates of NTM after initial successful treatment remain high, likely due to nonmodifiable risk factors raising the question of whether secondary prophylaxis is feasible. More rapid and readily available methods for detecting inducible macrolide resistance and better in vitro susceptibility testing methods for other drugs that correlate with clinical responses are needed. This is crucial to identify more effective regimens of existing drugs and for development of novel drugs for NTM infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.